In liver transplant, during anti-viral therapy for hepatitis C virus (HCV) recurrence, the immunosuppressant levels should be monitored to prevent both toxicity and rejection. Sofosbuvir (SOF) has been used within compassionate programs for HCV recurrence and, according to pharmacokinetic analyses, is not supposed to have significant pharmacological interactions with tacrolimus (Tac) or ciclosporin.1 This was reported in the review article by Koff recently published.2 We treated eight transplant recipients with SOF/ribavirin (RBV) for a severe HCV recurrence, and observed unexpected Tac/ciclosporin reduction during SOF.

Calcineurin inhibitors levels reduction during treatment with Sofosbuvir in liver transplanted patients / Vukotic, Ranka; Morelli, M; Pinna, Antonio Daniele; Margotti, Marzia; Foschi, Fg; Loggi, Elisabetta; Bernardi, Mauro; Andreone, Pietro. - In: ALIMENTARY PHARMACOLOGY & THERAPEUTICS. - ISSN 0269-2813. - 40:(2014), pp. 405-405. [10.1111/apt.12853]

Calcineurin inhibitors levels reduction during treatment with Sofosbuvir in liver transplanted patients

VUKOTIC, RANKA;PINNA, ANTONIO DANIELE;MARGOTTI, MARZIA;BERNARDI, MAURO;ANDREONE, PIETRO
2014

Abstract

In liver transplant, during anti-viral therapy for hepatitis C virus (HCV) recurrence, the immunosuppressant levels should be monitored to prevent both toxicity and rejection. Sofosbuvir (SOF) has been used within compassionate programs for HCV recurrence and, according to pharmacokinetic analyses, is not supposed to have significant pharmacological interactions with tacrolimus (Tac) or ciclosporin.1 This was reported in the review article by Koff recently published.2 We treated eight transplant recipients with SOF/ribavirin (RBV) for a severe HCV recurrence, and observed unexpected Tac/ciclosporin reduction during SOF.
2014
40
405
405
Calcineurin inhibitors levels reduction during treatment with Sofosbuvir in liver transplanted patients / Vukotic, Ranka; Morelli, M; Pinna, Antonio Daniele; Margotti, Marzia; Foschi, Fg; Loggi, Elisabetta; Bernardi, Mauro; Andreone, Pietro. - In: ALIMENTARY PHARMACOLOGY & THERAPEUTICS. - ISSN 0269-2813. - 40:(2014), pp. 405-405. [10.1111/apt.12853]
Vukotic, Ranka; Morelli, M; Pinna, Antonio Daniele; Margotti, Marzia; Foschi, Fg; Loggi, Elisabetta; Bernardi, Mauro; Andreone, Pietro
File in questo prodotto:
File Dimensione Formato  
Calcineurin APT.pdf

Accesso riservato

Dimensione 90.29 kB
Formato Adobe PDF
90.29 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1237191
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 4
social impact